# GSK to acquire Chimagen Trispecific T-cell engager for multiple myeloma

- Link: https://www.directorstalkinterviews.com/gsk-to-acquire-chimagen-trispecific-t-cell-engager-for-multiple-myeloma/4121262536
- Published: 2026-09-15T07:09:00+01:00
- Author: Amilia Stone

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**(
[LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l),
NYSE: GSK) has announced it has entered an agreement to acquire a potential best-
in-class trispecific T cell-engager (TCE) from Chimagen Biosciences (Chimagen), 
a privately held biotechnology company. GSK plans to develop and commercialise the
asset for multiple myeloma, with the programme expected to enter phase I trials 
in 2027.

TCEs have shown transformational efficacy in multiple myeloma but have been associated
with difficult tolerability profiles. The Chimagen trispecific asset is designed
to address this by binding to T cells while simultaneously targeting two strategically
selected and validated tumour-associated antigens. This targeted approach aims to
achieve a deeper and more durable response compared to existing TCEs, along with
an improved tolerability profile. This could enable broader adoption and earlier
use in multiple myeloma treatment, providing an important advancement for patients
who may require multiple options depending on their treatment needs. The US TCE 
market for multiple myeloma is expected to exceed $10 billion by 2032.^([1])

> **Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said:**“
> Today’s deal secures a promising T cell engager and advances GSK’s leadership 
> goals in blood cancer. The agreement complements our existing portfolio in multiple
> myeloma, adding a new potential option to address the different needs of patients
> facing this complex disease.”

> **Zhenhao Zhou, Chief Executive Officer, Chimagen Biosciences, said**: “Our mission
> has always been to translate cutting-edge innovation into life-changing medicines.
> Working with GSK combines our precision T-cell engager programme with their global
> development and commercial capabilities to redefine care for multiple myeloma 
> patients. This agreement also marks another major milestone for our platforms 
> as we continue to build an industry-leading pipeline of multi-specific antibody
> candidates.”

Multiple myeloma is the third most common blood cancer globally, with approximately
180,000 new cases diagnosed globally each year.^([2],[3]) While generally considered
treatable, it is not currently curable, and research into new therapies is vital
as the disease commonly becomes refractory to available treatments.^([4])

The agreement builds on GSK’s existing relationship with Chimagen, following a previous
agreement to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted TCE currently
in phase I trials for B-cell malignancies and B-cell dependent autoimmune disorders.

**Financial considerations**

Under the terms of the agreement, GSK will pay an upfront fee to acquire full global
rights to the TCE programme. Chimagen will also be eligible to receive success-based
development and commercial milestone payments. The agreement has a total potential
value of up to $750 million.

This agreement is subject to customary closing conditions.

^([1]) External commercial forecasts.

^([2]) Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics 2020: GLOBOCAN
Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. 
CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660.

^([3]) Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy.
Semin Oncol. 2016;43(6):676–681.doi: 10.1053/j.seminoncol.2016.11.004.

^([4]) Global Cancer Observatory. International Agency for Research on Cancer. World
Health Organization. Multiple Myeloma fact sheet. Available at: https://gco.iarc.
who.int/media/globocan/factsheets/cancers/35-multiple-myeloma-fact-sheet.pdf. Accessed
5 March 2025.

Share on:
